Biogen Inc. (BIIB) Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium Transcript
Summarize this article with:
SA Transcripts158.38K FollowersFollow5ShareSaveCommentsQ4: 2026-02-06 Earnings SummaryInsightsTranscript InsightsPlay CallPlay CallTranscriptEPS of $1.99 beats by $0.37 | Revenue of $2.28B (-7.14% Y/Y) beats by $75.58M Biogen Inc. (BIIB) Piper Sandler Virtual Novel Targets in Immunology Symposium February 13, 2026 10:30 AM EST Company Participants Diana Gallagher - Head of AD, MS & Immunology Development Units Conference Call Participants David Amsellem - Piper Sandler & Co., Research Division Presentation David AmsellemPiper Sandler & Co., Research Division Okay, good morning, everyone. And as I keep saying this morning, happy Friday the 13th, but on a serious note, we're delighted to be hosting our Virtual Immunology Symposium. This is David Amsellem from the Piper Sandler Biopharma Research Team. And we're delighted to have Biogen with us for the next 25 minutes or so. So we have Dr. Diana Gallagher. She is the Head of Clinical Development for MS Immunology and Alzheimer's. So thanks so much, Diana, for taking the time to chat with us. Certainly, there's a great deal going on regarding Biogen's immunology pipeline and some late-stage readouts that are coming. Question-and-Answer Session David AmsellemPiper Sandler & Co., Research Division Maybe I'll start with your lupus programs. So you have dapirolizumab and litifilimab, both in late-stage development. But I wanted to ask a high-level question on the strategic rationale of prioritizing lupus, specifically SLE and other manifestations of the disease given that it's historically been such a challenging space in terms of drug development. So I guess with that in mind, why such a big priority to lupus? Obviously, it's a major unmet medical need. But just given the challenges, maybe talk about your thought process here. Diana GallagherHead of AD, MS & Immunology Development Units Sure. So we've been working -- first of all, thanks for having me, David. We're really excited to be here. And you're right, lupus remains a very underserved, heterogeneous disease area, major unmet need, where patients need more treatment options. We have been working in lupus. It's not new for